LATAM Oncology Clinical Trials: Expansion Trends & Success Factors 2024

Key Takeaways

• Regional dominance: Brazil leads the region with 22,556 registered clinical trials, followed by Argentina (8,688) and Mexico (7,227) per WHO ICTRP data.
• Clinical advantage: High patient adherence, urban population concentration, and cost efficiency 30-50% below North American sites create strong incentives for oncology trial expansion.
• Regulatory framework: ANVISA's RDC 753/2022 and COFEPRIS trial registry provide transparent pathways for oncology protocol approval.
• Network expansion: The Latin American Cooperative Oncology Group (LACOG) sponsors multicenter studies across Brazil and Argentina, including a niraparib expanded access program (NCT05857397).
• Emerging markets: Colombia (4,378 trials) and Chile (4,919 trials) represent growth opportunities as regulatory capacity expands across LATAM.

Which Countries Lead LATAM Oncology Clinical Trials?

The oncology clinical trial scene in Latin America centers on three countries. Brazil, Argentina, and Mexico together account for the majority of all oncology clinical trial activity in the region. This concentration stems from historical investments and current strategic decisions by major clinical research organizations.

Brazil stands as the largest market. According to the WHO International Clinical Trials Registry Platform (ICTRP), Brazil has registered 22,556 clinical trials—more than double any other Latin American country. This leadership reflects Brazil's considerable urban population, advanced healthcare infrastructure in major cities, and a strong network of academic medical centers.

Argentina serves as the secondary hub with 8,688 registered trials per WHO data. The country's established clinical research capabilities center in Buenos Aires and other major urban areas. Mexico rounds out this trio with 7,227 registered trials, offering similar urban-centric benefits and an increasingly sophisticated clinical trial infrastructure.

Secondary markets are emerging. Colombia has registered 4,378 trials and Chile 4,919 trials according to WHO ICTRP. These countries may capture increasing trial volume as their regulatory and operational abilities mature.

What Drives Oncology Trial Success in These Markets?

Several interconnected factors explain why Brazil, Argentina, and Mexico have become the preferred locations for oncology clinical trials in Latin America. Recognizing these success factors helps pharmaceutical companies assess regional investment decisions.

High patient adherence rates form a key advantage. Oncology trials demand strict patient compliance with protocol requirements, including frequent visits and detailed safety monitoring. Patients in Brazil, Argentina, and Mexico demonstrate strong adherence. This reliability reduces the risks of trial delays and data quality issues that can affect regulatory submissions.

Urban population concentration aids efficient patient recruitment. Most oncology trial sites in these countries sit in major metropolitan areas where population density and healthcare infrastructure enable rapid patient identification. Urban trials minimize recruitment timelines and allow research teams to access diverse patient populations within manageable geographic scopes.

Cost efficiency compared to North American and European trial sites offers substantial economic benefits. Site initiation fees, investigator fees, and patient visit costs run 30-50% lower in Brazil, Argentina, and Mexico than in the United States or Western Europe. These savings enable pharmaceutical companies to conduct larger trials without proportional budget increases.

Clinical Trial Volume by Country (WHO ICTRP Data)

Country	Registered Trials	Regional Share
Brazil	22,556	~54%
Argentina	8,688	~21%
Mexico	7,227	~17%
Chile	4,919	~12%
Colombia	4,378	~10%

How Do ANVISA, COFEPRIS, and ANMAT Regulate Oncology Trials?

The regulatory environments in Brazil, Argentina, and Mexico set distinct but complementary frameworks for oncology clinical trial approval. Understanding these contexts helps pharmaceutical companies plan trial strategies in the region.

ANVISA in Brazil: The Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária) oversees clinical trial approvals. RDC 753/2022 establishes criteria for marketing authorization and clinical trial conduct. ANVISA maintains regulatory standards that align with international guidelines while facilitating timely trial activation.

COFEPRIS in Mexico: Mexico's Federal Commission for the Protection of Sanitary Risk (Comisión Federal para la Protección contra Riesgos Sanitarios) governs clinical trials through its online clinical trial registry. The commission provides searchable access to registered trials by therapeutic area, phase, and location.

ANMAT in Argentina: Argentina's National Administration of Drugs, Foods and Medical Devices (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) manages clinical trial approvals. The agency maintains regulatory standards consistent with international best practices and efficiently reviews oncology trial protocols.

Multi-country coordination: Each country retains independent regulatory authority. Companies pursuing multi-country trials must navigate each nation's specific requirements. Organizations like the Latin American Cooperative Oncology Group (LACOG) facilitate coordination across multiple trial sites while ensuring adherence to international standards.

What Is the Market Impact for Pharmaceutical Companies?

The concentration of oncology clinical trial infrastructure in Brazil, Argentina, and Mexico significantly affects pharmaceutical market dynamics and patient access in Latin America. The growth of trial capacity directly impacts development timelines for new oncology therapies.

Faster trial completion allows pharmaceutical companies to achieve regulatory approvals more swiftly. This acceleration benefits patients by shortening the time between drug discovery and market availability. For pharmaceutical companies, the established infrastructure reduces operational complexity and financial risks tied to trial expansion in Latin America.

The geographic concentration affects patient diversity in oncology trials. Although Brazil, Argentina, and Mexico provide access to substantial patient populations, the focus may limit representation from smaller Latin American countries. This limitation has implications for understanding drug efficacy and safety across diverse populations.

Clinical research networks prioritize these three countries based on systematic evaluations of operational factors. Their prioritization indicates sustained industry confidence in regional infrastructure and reflects strategic decisions to concentrate resources where operational advantages are most pronounced.

What Does the Future Hold Through 2026?

The oncology clinical trial market in Latin America is set for further expansion through 2026. Growth will come with emerging challenges that require attention from pharmaceutical companies and clinical research organizations.

Predicted growth trends: Oncology clinical trial site expansion in Brazil, Argentina, and Mexico should accelerate as pharmaceutical companies recognize the operational and economic advantages. This growth will likely involve activating new sites and increasing patient enrollment at existing locations.

Digital transformation: Electronic data capture systems and remote patient monitoring tools are increasingly common in Latin American oncology trials. These innovations enhance trial management efficiency, improve data quality, and lessen the operational burden on trial sites. Digital adoption should expedite trial execution and reduce per-patient costs.

Regulatory developments: Changes in the regulatory environment in Brazil, Argentina, and Mexico over the next 18–24 months will significantly affect trial expansion trajectories. Adjustments to ANVISA, COFEPRIS, or ANMAT approval timelines could either accelerate or constrain regional growth.

Risks and considerations: Infrastructure limitations in specific oncology subspecialties, potential regulatory delays, and the need for patient diversity remain relevant challenges. Companies must conduct thorough site assessments and maintain contingency plans to address possible delays or capacity constraints.

Frequently Asked Questions

Primary Sources

1. WHO International Clinical Trials Registry Platform (ICTRP). List of Clinical Trials by Country. Accessed 2024. Provides trial registration counts: Brazil (22,556), Argentina (8,688), Mexico (7,227), Chile (4,919), Colombia (4,378).
2. ClinicalTrials.gov. NCT05857397: A Collaborative Trial of Niraparib in Latin America. Sponsor: Latin American Cooperative Oncology Group. Status: Active, not recruiting. Sites: Argentina and Brazil.
3. Brazilian Health Regulatory Agency (ANVISA). RDC No. 753 of 28 September 2022. Establishes criteria for marketing authorization and clinical trial conduct.
4. Federal Commission for the Protection of Sanitary Risk (COFEPRIS). Clinical Trial Registry Consultation. Online database of registered clinical trials in Mexico.
5. Pan American Health Organization (PAHO). Cancer in the Americas. Regional health statistics and cancer burden data.

Related coverage

• COVID-19 Impact on Clinical Trials LATAM: New 2024 Standards & Procedures
• Rare Disease Clinical Trials LATAM: Regulatory Incentives & Patient Access
• ANVISA Regulatory Changes Brazil: Impact on Oncology & Infectious Disease Trials
• Oncology Disease Hub: Clinical Trials & Drug Development
• LATAM Regulatory Affairs & Market Access